Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

To target or not to target APRIL in systemic lupus erythematosus: that is the question!

Jacques Morel123* and Michael Hahne234

Author affiliations

1 Department of Rheumatology, CHU Lapeyronie, 191 Avenue du Doyen Gaston, Giraud, 34295 Montpellier, Cedex 5, France

2 Institut de Génétique Moléculaire de Montpellier, CNRS, UMR5535, 1919 route de Mende, 34293 Montpellier, France

3 Université Montpellier 1, 5 Boulevard Henri IV, 34000 Montpellier, Cedex 5, France

4 Université Montpellier 2, Place Eugène Bataillon, 34095 Montpellier, Cedex 5, France

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2013, 15:107  doi:10.1186/ar4160


See related research by Treamtrakanpon et al., http://arthritis-research.com/content/14/6/R252

Published: 25 February 2013

Abstract

Among the cytokines that regulate B-cell homeostasis are the TNF-like ligands B-lymphocyte stimulator (BLyS; also B-cell activation factor) and a proliferation-inducing ligand (APRIL). BLyS and APRIL share two receptors; that is, B-cell maturation antigen and transmembrane activator and CAML interactor. Therapeutic approaches using biologics are limited for treatment of lupus patients. One previously approved drug is belimumab, which antagonizes the B-cell stimulator BLyS. Atacicept, another biologic inhibiting BLyS and APRIL, was terminated for serious adverse events - raising the question of whether APRIL should be neutralized in autoimmune diseases.